Morgan Stanley Ovid Therapeutics Inc. Transaction History

Morgan Stanley

$1.36 Trillion
Q1 2025

A detailed history of Morgan Stanley transactions in Ovid Therapeutics Inc. stock. As of the latest transaction made, Morgan Stanley holds 82,727 shares of OVID stock, worth $23,990. This represents 0.0% of its overall portfolio holdings.

Number of Shares

82,727

Previous 189,487 56.34%

Holding current value

$23,990

Previous $176,000 85.8%

% of portfolio

0.0%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	SELL	$0.31 - $0.96 $33,095 - $102,489	-106,760 Reduced 56.34%	82,727 $25,000
Q4 2024 Feb 14, 2025	BUY	$0.93 - $1.36 $22,001 - $32,173	23,657 Added 14.27%	189,487 $176,000
Q3 2024 May 14, 2025	BUY	$0.75 - $1.3 $72,660 - $125,944	96,880 Added 140.51%	165,830 $195,000
Q3 2024 Nov 14, 2024	BUY	$0.75 - $1.3 $72,660 - $125,944	96,880 Added 140.51%	165,830 $195,000
Q2 2024 May 14, 2025	SELL	$0.7 - $3.34 $84,375 - $402,593	-120,537 Reduced 63.61%	68,950 $53,000
Q2 2024 Oct 17, 2024	SELL	$0.7 - $3.34 $21,702 - $103,550	-31,003 Reduced 31.02%	68,950 $53,000
Q2 2024 Aug 14, 2024	SELL	$0.7 - $3.34 $21,702 - $103,550	-31,003 Reduced 31.02%	68,950 $53,000
Q1 2024 Oct 17, 2024	BUY	$2.72 - $4.04 $84,328 - $125,252	31,003 Added 44.96%	99,953 $304,000
Q1 2024 Aug 16, 2024	SELL	$2.72 - $4.04 $92,444 - $137,307	-33,987 Reduced 25.37%	99,953 $304,000
Q1 2024 May 15, 2024	SELL	$2.72 - $4.04 $92,444 - $137,307	-33,987 Reduced 25.37%	99,953 $304,000
Q4 2023 Aug 16, 2024	BUY	$2.98 - $3.78 $193,670 - $245,662	64,990 Added 94.26%	133,940 $431,000
Q4 2023 Feb 13, 2024	BUY	$2.98 - $3.78 $270,652 - $343,310	90,823 Added 210.64%	133,940 $431,000
Q3 2023 Nov 15, 2023	SELL	$3.23 - $3.97 $34,002 - $41,792	-10,527 Reduced 19.62%	43,117 $165,000
Q2 2023 Aug 14, 2023	BUY	$2.53 - $3.89 $52,578 - $80,841	20,782 Added 63.24%	53,644 $175,000
Q1 2023 May 15, 2023	BUY	$1.88 - $2.85 $55,123 - $83,564	29,321 Added 828.04%	32,862 $84,000
Q4 2022 Feb 14, 2023	SELL	$1.43 - $1.89 $17,900 - $23,659	-12,518 Reduced 77.95%	3,541 $6,000
Q3 2022 Nov 14, 2022	SELL	$1.84 - $2.26 $8,854 - $10,875	-4,812 Reduced 23.06%	16,059 $30,000
Q2 2022 Oct 27, 2022	BUY	$1.69 - $3.31 $3,043 - $5,961	1,801 Added 9.44%	20,871 $45,000
Q2 2022 Aug 15, 2022	BUY	$1.69 - $3.31 $3,043 - $5,961	1,801 Added 9.44%	20,871 $45,000
Q1 2022 Oct 27, 2022	SELL	$2.65 - $3.49 $4,772 - $6,285	-1,801 Reduced 8.63%	19,070 $60,000
Q1 2022 May 13, 2022	SELL	$2.65 - $3.49 $6,346 - $8,358	-2,395 Reduced 11.16%	19,070 $60,000
Q4 2021 Feb 14, 2022	SELL	$3.13 - $3.73 $75,022 - $89,404	-23,969 Reduced 52.76%	21,465 $69,000
Q3 2021 Nov 15, 2021	BUY	$3.31 - $4.04 $150,386 - $183,553	45,434 New	45,434 $153,000

Others Institutions Holding OVID

# of Institutions

Shares Held

39.8M

Call Options Held

1.7K

Put Options Held

100

View Full List

About Ovid Therapeutics Inc.

Ticker OVID
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,419,400
Market Cap $20.4M
Description
Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment o...

More about OVID

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account